1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Specialties
Alcon AG

Alcon AG

0A0D.IL
Alcon AGGB flagInternational Order Book
59.01
CHF
-1.20
- -
28.76BMarket Cap
Alcon AG
0A0D.IL
(International Order Book)

Recent

price

59.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
13.5
13.9
14.64
15.38
13.97
16.92
17.74
19.18
20.05
21.09
21.65
Revenue per Share
-0.35
0.52
-0.46
-1.34
-1.09
0.77
0.68
1.98
2.06
1.99
1.67
Basic EPS, GAAP
1.51
1.48
0.88
0.5
0.52
0.34
0.96
1.09
2.85
3.26
3.24
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.11
0.2
0.24
0.26
0.34
- -
Dividend per Share
- -
47.12
46.32
39.53
38.47
39.29
40.15
41.81
43.58
- -
45.38
Book Value per Share
- -
5.31
6.26
0.34
1.68
3.24
2.17
5.35
8.13
- -
8.19
Tangible Book Value per Share
489
489
489
488
489
490
491
493
494
493
491
Basic Weighted Avg Shares
6,596
6,792
7,153
7,508
6,833
8,291
8,717
9,455
9,911
10,401
10,634
Sales/Revenue/Turnover
0.15
-1.13
-3.47
-2.49
-7.05
7
7.71
10.99
14.26
13.08
11.13
Operating Margin (%)
1,289
1,305
1,622
1,425
1,623
1,219
1,123
1,221
1,228
1,335
1,347
Depreciation Expense
-170
256
-227
-656
-531
376
335
974
1,018
980
819
Net Income, GAAP
- -
- -
- -
- -
- -
10.05
27.65
- -
18.95
15.52
16.94
Effective Tax Rate (%)
-2.58
3.77
-3.17
-8.74
-7.77
4.54
3.84
10.3
10.27
9.42
7.7
Profit Margin (%)
- -
1,509
1,506
1,936
2,729
2,914
2,455
3,249
4,031
3,400
3,616
Working Capital
- -
84
89
3,498
4,264
4,305
4,900
5,011
429
429
4,605
LT Debt
- -
23,029
22,639
19,303
18,822
19,256
19,677
20,624
21,553
- -
22,133
Total Equity
- -
- -
- -
- -
- -
2.2
1.99
- -
4.75
10.14
3.58
Return on Invested Capital (%)
- -
- -
- -
- -
- -
2.06
1.78
- -
4.9
10.21
3.63
Return on Capital (%)
- -
2.22
-0.99
-3.13
-2.79
1.97
1.72
4.83
4.83
- -
3.71
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
647
- -
648
LT Borrowings
4,163
- -
4,157
LT Finance Leases
428
429
448
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
491
487
488
Market Capitalization
36,392
38,858
36,199

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6,333
6,449
6,620
Cash, Cash Equivalents & STI
1,498
- -
1,659
Accounts Receivable, Net
1,908
- -
1,981
Inventories
2,433
2,391
2,438
Total Current Liabilities
2,990
3,049
3,004
Payables & Accruals
1,091
- -
1,127
ST Debt
647
- -
648
Deferred Revenue
- -
84
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
68.12%
14.29%
Net Income, GAAP
- -
1.97%
-3.73%
Sales/Revenue/Turnover
- -
8.94%
4.94%
Total Cash Common Dividend
- -
- -
27.69%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,459
2,496
2,454
2,502
9,911
2025
2,473
2,596
2,614
2,718
10,401
2026
2,706
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.5
0.45
0.53
0.57
2.06
2025
0.71
0.36
0.48
0.44
1.99
2026
0.39
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.26
2025
- -
- -
- -
- -
0.34
2026
- -
- -
- -
- -
- -
Similar Companies
Spectral Medical Inc (EDTXF)
Ray Co., Ltd. (228670.KQ)
Eckert & Ziegler SE (0NZY.IL)
Masimo Corporation (0JZ2.L)
Wholehealth Products, Inc. (GWPC)
Shanghai United Imaging Healthcare Co., Ltd. (688271.SS)
Business
Alcon AG is a globally active ophthalmology company that researches, develops, manufactures, and markets eye-care products and surgical equipment for vision correction, cataract and refractive surgery, retina and corneal therapies, and related diagnostic and support services. Main products and services include intraocular lenses (IOLs) and cataract devices; vitreoretinal equipment and accessories; refractive and cataract surgery products; corneal and refractive surgery technologies; diagnostic instruments and imaging systems; ophthalmic pharmaceuticals and irrigating solutions; service and maintenance for surgical equipment; and related training and education programs for clinicians. The company operates as a Swiss-registered entity with headquarters in Basel, Switzerland, and maintains commercial and manufacturing operations across the Americas, Europe, the Middle East and Africa, and Asia-Pacific regions. Founding year and headquarters: established in 1945; headquarters in Basel, Switzerland. Subsidiaries and parent relationships include global manufacturing facilities and regional subsidiaries that support direct sales, distribution, and service networks. Latest major changes: enters strategic alliances with healthcare providers and distributors to expand geographic reach; completes acquisitions and integration of ophthalmic device portfolios; launches new imaging and surgical technology platforms; expands service offerings including remote monitoring and training programs; undergoes organizational reorganizations to streamline regional operations and enhance R&D collaboration; secures funding rounds to accelerate growth in next-generation lens and surgical platform development. Industry and segments: ophthalmic devices and solutions; vision care products; surgical equipment and instruments; diagnostic imaging and analytics; clinical training and support services. Target markets include ophthalmology clinics, hospitals, surgical centers, and independent eye-care practitioners worldwide. Geographic operations span North America, Latin America, Europe, Middle East and Africa, and Asia-Pacific. Founding year and headquarters location reaffirmed above, with a global network of manufacturing sites, regional sales offices, and distribution partners.